Delving into the Latest Updates on Aflibercept with Synapse

Overview

Basic Info

Drug Type

Fc fusion protein

Synonyms

Aflibercept (Genetical Recombination), Aflibercept (genetical recombination) (JAN), Aflibercept (USAN/INN)

+ [13]

Target

PGF x VEGF-A

Action

inhibitors

Mechanism

PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)

Therapeutic Areas

NeoplasmsCardiovascular DiseasesCongenital Disorders+ [7]

Active Indication

Retinopathy of PrematurityGlaucoma, NeovascularColorectal Cancer+ [21]

Inactive Indication

Adenocarcinoma of large intestineAdvanced Malignant Solid NeoplasmAngioid Streaks+ [38]

Originator Organization

Regeneron Pharmaceuticals, Inc.

Active Organization

Regeneron Pharmaceuticals, Inc.

Sanofi

Bayer AG

+ [8]

Inactive Organization

Sanofi-Aventis Recherche & Développement SA

Sanofi-Aventis Deutschland GmbH

Santen Pharmaceutical Co., Ltd.

+ [2]

License Organization

Santen Pharmaceutical Co., Ltd.

Ocular Therapeutix, Inc.Bayer Korea Ltd.

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (18 Nov 2011),

Wet age-related macular degeneration

RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 4715606

Source: *****

This is a 12-month, prospective, randomized controlled, multi-center, open-label, superiority designed study. Treatment-Naïve DME patient with inflammatory biomarkers, who meet the inclusion and exclusion criteria, will be recruited.
This study aims to provide the first direct comparative evidence within a Chinese cohort, evaluating the efficacy and safety of a combined DEX-I plus aflibercept therapy versus aflibercept monotherapy for DME. The investigation will focus on functional visual outcomes, anatomical improvements, and the respective safety profiles associated with each treatment regimen. Furthermore, the study will incorporate specific optical coherence tomography (OCT) biomarkers to refine patient selection, with the goal of enhancing the precision of identifying candidates for combination therapy.
It is hypothesized that the combination therapy, by concurrently targeting both VEGF-mediated and inflammatory pathways, may yield superior clinical outcomes compared to monotherapy.

Start Date15 Mar 2026

Sponsor / Collaborator

Shanghai First People's Hospital

[+7]

NCT07340372

/ Not yet recruitingNot ApplicableIIT

Home Monitoring in eAMD Treatment

The goal of this observational clinical study is to collect more information about the efficacy of Aflibercept 8 mg injections in people with eAMD. The main questions it aims to answer are:
* To reassure patients and doctors with longer intervals using home monitoring app;
* To assess patient reported outcomes (PROMs) and Value-based Healthcare.
Participants already taking Aflibercept 8 mg as part of their regular medical care for eAMD will undergo regular ophthalmological examination and use a home monitoring app, in a one year and a two-year treatment period.

Start Date01 Mar 2026

Sponsor / Collaborator

Association For Innovation & Biomedical Research

100 Clinical Results associated with Aflibercept

Login to view more data

100 Translational Medicine associated with Aflibercept

Login to view more data

100 Patents (Medical) associated with Aflibercept

Login to view more data

3,397

Literatures (Medical) associated with Aflibercept

01 May 2026·Value in Health Regional Issues

Cost-Effectiveness of Vascular Endothelial Growth Factor Inhibitors in the Management of Wet Age-Related Macular Degeneration: A Systematic Review

Article

Author: Paneerselvam, Ganesh S ; Kenneth, Lee K C ; Wai, Ng J ; Sheng, Lim J

OBJECTIVES:

To evaluate the cost-effectiveness of VEGF inhibitors, ranibizumab, aflibercept, bevacizumab, brolucizumab, pegaptanib, and conbercept for wAMD treatment.

METHODS:

A systematic search was conducted in PubMed, Cochrane, and SpringerLink databases to identify cost-effectiveness analyses and cost-utility analyses related to wAMD treatment. Eligible studies were assessed using Drummond's 10-point checklist to evaluate methodological quality. The extracted data included intervention costs, quality-adjusted life-years, and incremental cost-effectiveness ratios.

RESULTS:

Twenty-two studies met the inclusion criteria. Bevacizumab and brolucizumab were frequently reported as cost-effective alternatives, offering comparable or superior visual outcomes at lower costs than ranibizumab or aflibercept. Pegaptanib was consistently less cost-effective. Findings for ranibizumab versus aflibercept varied by treatment regimen and analytic assumptions. Across studies, cost-effectiveness estimates were influenced by model perspective, time horizon, exclusion of adverse events, and single-eye modeling. A further limitation is that in contexts of non-inferior efficacy, small incremental quality-adjusted life-years differences may artificially inflate incremental cost-effectiveness ratios, potentially overstating the costs relative to benefits.

CONCLUSIONS:

Decision making in wAMD treatment requires more thorough economic evaluations that incorporate standardized methodologies and lengthy cost assessments.

01 Mar 2026·Pakistan Journal of Pharmaceutical Sciences

The Impact Of Aflibercept Combined With Dexamethasone Intravitreal Implant On Visual Function And Aqueous Humor Inflammatory Responses In Diabetic Macular Edema

Article

Author: Luo, Dan

Background: Diabetic macular edema (DME) is a predominant cause of visual impairment among patients. The concurrent administration of anti-vascular endothelial growth factor (VEGF) agents and corticosteroids may yield synergistic therapeutic benefits. Objective: In this study, we evaluated the efficacy and safety of aflibercept (AFL) in combination with dexamethasone (DEX) intravitreal implant for the treatment of DME. Methods: A total of 80 patients with DME admitted to a hospital from June 2022 to June 2024 were enrolled. 42 patients in the AFL group received monotherapy, and 38 patients in the AFL+DEX group received combination therapy. The best corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP) and aqueous humor inflammatory factors (IL-1?, MCP-1, IL-6, VEGF) were evaluated monthly. Efficacy was graded according to criteria at 4 months after treatment, and adverse events were recorded. Results: The findings revealed no statistically significant difference in the overall clinical efficacy rate between the AFL+DEX group and the AFL group (P>0.05). However, the AFL+DEX group demonstrated superior best-corrected visual acuity (BCVA) at 1, 3 and 6 months post-treatment, alongwith a significant reduction in central macular thickness (CMT) compared to the AFL group (P<0.05). Furthermore, aqueous humor analysis indicated markedly lower levels of inflammatory cytokines in the AFL+DEX group following treatment (P<0.05). In terms of safety profiles, the AFL+DEX group required fewer intravitreal injections (P<0.05). Conclusion: These findings underscore the potential of AFL combined with DEX intravitreal implant to enhance visual outcomes and modulate intraocular inflammation in DME patients, highlighting its substantial clinical utility.

01 Mar 2026·BIOMEDICINE & PHARMACOTHERAPY

Comparative effectiveness and safety landscape of anti-VEGF therapies for neovascular age-related macular degeneration: Insights from a systematic review and network meta-analysis

Article

Author: Chen, Kai-Yang ; Chan, Chi-Ming ; Chan, Hoi-Chun

INTRODUCTION:

Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss in older adults. Intravitreal anti-vascular endothelial growth factor (VEGF) agents-including Aflibercept, Ranibizumab, Bevacizumab, Brolucizumab, and Faricimab-are the mainstay of therapy. However, their comparative efficacy and safety remain uncertain. This study aimed to compare the visual and systemic outcomes of these agents to inform clinical decision-making.

METHODS:

A systematic search of PubMed, Embase, Scopus, and Web of Science from inception to September 2025 identified randomized controlled trials (RCTs) and observational studies comparing at least two anti-VEGF agents in nAMD. Eligible studies reported outcomes of best-corrected visual acuity (BCVA) change, visual gain ≥ 15 letters, mortality, or arteriothrombotic events. Risk of bias was assessed using Cochrane Risk of Bias 2 (RoB 2) and Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tools. A frequentist network meta-analysis estimated mean differences (MD) and odds ratios (OR) with 95 % confidence interval (CI). The protocol was registered in PROSPERO (CRD42025631298).

RESULTS:

Sixteen studies involving 6758 participants (follow-up 3-24 months) met the inclusion criteria. For BCVA improvement, Aflibercept had the highest surface under the cumulative ranking curve (SUCRA) ranking (0.80), although all agents showed similar mean differences that were not statistically significant: aflibercept (MD 0.80; 95 % CI -1.20-2.80), Ranibizumab (0.64; -1.87-3.15), Bevacizumab (0.60; -2.02-3.22), Faricimab (2.20; -0.69-5.09), and Brolucizumab (4.20; -5.97-14.36). The larger point estimate for Brolucizumab reflects imprecision rather than superior visual efficacy. Mortality was lowest with Aflibercept (risk ratio (RR) 0.76; 95% CI 0.41-1.55). For arteriothrombotic events, no statistically significant differences were observed between anti-VEGF agents. Comparisons between Aflibercept and Bevacizumab (RR 1.11; 95% CI 0.60-2.07), aflibercept and Ranibizumab (RR 0.77; 95% CI 0.49-1.21), and Bevacizumab and Ranibizumab (RR 0.88; 95% CI 0.60-1.30) showed wide confidence intervals, reflecting substantial imprecision. Certainty of evidence (GRADE) ranged from moderate to low.

CONCLUSION:

All anti-VEGF agents stabilize or improve vision in nAMD. Aflibercept may provide the most favorable efficacy-safety balance, Faricimab offers promising durability, and Brolucizumab demonstrates large visual gains with potential safety concerns. Further head-to-head and long-term real-world studies are needed to optimize individualized treatment strategies.

817

News (Medical) associated with Aflibercept

04 Mar 2026

·firstwordpharma.com

Bayer sees accelerating declines this year for Xarelto, Eylea

Bayer said Wednesday that it expects the erosion of Xarelto sales to "slightly accelerate" this year as the oral anticoagulant faces further competition from generics. Revenue from the product is forecast to fall by between 35% and 40% in 2026, compared to a roughly 33% decline last year to €2.3 billion ($2.7 billion).The company noted that Xarelto's performance in 2025 was impacted by competitive pressure from generics in Japan and Russia, in addition to ongoing at-risk launches in Europe.Bayer also expects lower overall sales of Eylea this year amid "significant" pricing pressure, with revenue from the anti-VEGF therapy predicted to fall by between 20% and 25%, versus a drop of 6% to €3.1 billion in 2025. Sales last year were also affected by lower prices, especially in Canada, the UK and Japan.Sales of the 2-mg version of Eylea — which is facing biosimilar competition — slipped 24% to €2.3 billion. Stefan Oelrich, head of Bayer's pharmaceuticals division, conceded that the company "may have slightly underestimated" the impact of biosimilars, but "will continue to closely observe and evaluate the evolving situation." Meanwhile, revenue from the newer, 8-mg version of Eylea surged 274% to €819 million, contributing 26% to the overall franchise, with "continued uptake" of the product set to continue in 2026. Oelrich said Bayer hopes to expand the higher dose version's contribution to the Eylea franchise to approximately 70%.Nubeqa, Kerendia outperform Offsetting the performance of Xarelto and Eylea, Bayer's growth products — led by prostate cancer drug Nubeqa and chronic kidney disease treatment Kerendia — helped the company's pharmaceutical division post a 2% increase in sales last year to €17.8 billion.Nubeqa sales rose 57% to €2.4 billion, while Kerendia climbed 79% to €829 million. "Nubeqa and Kerendia continued their significant growth momentum and finished the year ahead of our raised expectations," said Chief Financial Officer Wolfgang Nickl.For the coming year, Oelrich indicated that the momentum for Nubeqa and Kerendia is set to continue, with "expected growth of approximately 50% at constant currencies."Bayer also confirmed that it has removed ACTUS-101 from its pipeline, having previously disclosed that recruitment in a Phase I trial of the AAV gene therapy for late-onset Pompe disease had been halted. The company gained ACTUS-101 via the $4-billion takeover of Asklepios BioPharmaceutical (AskBio) in 2020.($1 = €0.85856075)

AcquisitionPhase 1Gene TherapyDrug ApprovalBiosimilar

03 Mar 2026

·retinalphysician.com

Axpaxli Data Presented at Macula Society Meeting

At a symposium during the 49th meeting of the Macula Society in Coronado, California, Ocular Therapeutix presented detailed results from its phase 3 SOL-1 trial evaluating Axpaxli (OTX-TKI) for neovascular age-related macular degeneration (nAMD). The intravitreal insert met its primary endpoint and demonstrated superiority to aflibercept. The company said the results are intended to support a new drug application to the US Food and Drug Administration (FDA) through an accelerated pathway. SOL-1 enrolled 344 treatment-naïve patients and compared a single injection of Axpaxli, a bioresorbable hydrogel incorporating the tyrosine kinase inhibitor axitinib, with aflibercept 2 mg (Eylea; Regeneron) following an 8-week loading regimen. At week 36, 74.1% of Axpaxli-treated patients maintained vision, defined as loss of fewer than 15 ETDRS letters, compared with 55.8% in the aflibercept arm (risk difference, 17.5%; P=.0006). At week 52, 65.9% of Axpaxli-treated patients maintained vision vs 44.2% in the aflibercept arm (risk difference, 21.1%; P<.0001). Rescue-free rates and central subfield thickness control were also higher with Axpaxli through week 36. Safety findings were consistent with prior studies, with no treatment-related ocular serious adverse events reported. During the symposium, lead investigator Arshad M. Khanani, MD, said Axpaxli is the first investigational agent with a novel mechanism of action to demonstrate superiority over an approved anti-VEGF therapy in an FDA-aligned study in wet AMD. Additional presentations included Dilsher S. Dhoot, MD, who discussed real-world treatment challenges in nAMD; Peter K. Kaiser, MD, who reviewed the mechanism of action; Jeffrey S. Heier, MD, who outlined the trial design; and Patricio G. Schlottmann, MD, who presented safety data. Mark R. Barakat, MD, and Adnan Tufail, MBBS, MD, presented case examples and key insights. The symposium concluded with a panel discussion. The study was conducted under a special protocol assessment agreement. A second phase 3 trial, SOL-R, is ongoing, with topline results expected in the first half of 2027. Prior to the symposium, Pravin U. Dugel, MD, executive chairman, president, and CEO of Ocular Therapeutix, spoke with Retinal Physician about the trials, the regulatory pathway for Axpaxli, and what the results could mean for the future of wet AMD care. That interview is available here. RP

Clinical ResultPhase 3

02 Mar 2026

·retinalphysician.com

EyePoint Begins Phase 3 Trials of Duravyu for DME

EyePoint Pharmaceuticals has dosed the first patients in 2 global phase 3 clinical trials evaluating Duravyu (formerly EYP-1901), an investigational sustained-delivery intravitreal therapy, for diabetic macular edema (DME). The studies, known as COMO and CAPRI, are designed to assess the safety and efficacy of a 6-month dosing regimen compared with on-label aflibercept (Eylea; Regeneron). Duravyu delivers vorolanib, a selective tyrosine kinase inhibitor, via a bioerodible intravitreal insert. Unlike anti-VEGF biologics that target extracellular ligands, vorolanib acts intracellularly to inhibit VEGF receptors and platelet-derived growth factor receptors, while also suppressing inflammation mediated by interleukin-6 signaling. Each randomized, double-masked trial is expected to enroll approximately 240 patients, including both treatment-naïve and previously treated individuals, the company reported at the 49th meeting of the Macula Society. Participants are assigned to receive either Duravyu 2.7 mg every 6 months or standard aflibercept injections. The primary endpoint is noninferiority in change from baseline best-corrected visual acuity at weeks 52 and 56. Secondary measures include treatment burden, supplemental injection use, safety, and optical coherence tomography outcomes. The phase 3 program follows a positive end-of-phase 2 meeting with the US Food and Drug Administration (FDA) and alignment with the European Medicines Agency. Topline data from the DME trials are expected in the second half of 2027. The vorolanib intravitreal insert is also being evaluated as a potential treatment for neovascular age-related macular degeneration (nAMD) in a pair of pivotal phase 3 trials, LUGANO and LUCIA, that have enrolled more than 900 patients. RP

Phase 3Phase 2

100 Deals associated with Aflibercept

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09574	Aflibercept	L01XX44 S01LA05	DB08885

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Retinopathy of Prematurity	Japan	Bayer Yakuhin Ltd.	26 Sep 2022
Glaucoma, Neovascular	Japan	Bayer Yakuhin Ltd.	25 Mar 2020
Colorectal Cancer	Japan	Sanofi KK	30 Mar 2017
Diabetic Retinopathy	United States	Regeneron Pharmaceuticals, Inc.	25 Mar 2015
Macular Edema	Japan	Bayer Yakuhin Ltd.	22 Nov 2013
Blindness	South Korea	Bayer Korea Ltd.	20 Mar 2013
Retinal Vein Occlusion	European Union	Bayer AG	21 Nov 2012
Retinal Vein Occlusion	Iceland	Bayer AG	21 Nov 2012
Retinal Vein Occlusion	Liechtenstein	Bayer AG	21 Nov 2012
Retinal Vein Occlusion	Norway	Bayer AG	21 Nov 2012
Choroidal Neovascularization	Japan	Bayer Yakuhin Ltd.	28 Sep 2012
Macular Degeneration, Age-Related, 1	Japan	Bayer Yakuhin Ltd.	28 Sep 2012
Metastatic Colorectal Carcinoma	United States	Sanofi-Aventis U.S. LLC	03 Aug 2012
Diabetic macular oedema	Australia	Bayer Australia Ltd.	07 Mar 2012
Myopic choroidal neovascularization	Australia	Bayer Australia Ltd.	07 Mar 2012
Retinal vein occlusion-related macular edema	Australia	Bayer Australia Ltd.	07 Mar 2012
Wet age-related macular degeneration	United States	Regeneron Pharmaceuticals, Inc.	18 Nov 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polypoidal choroidal vasculopathy	Phase 3	South Korea	Bayer AG	24 Dec 2026
Edema	Phase 3	United States	Bayer AG	15 May 2023
Edema	Phase 3	China	Bayer AG	15 May 2023
Edema	Phase 3	Japan	Bayer AG	15 May 2023
Edema	Phase 3	Australia	Bayer AG	15 May 2023
Edema	Phase 3	Austria	Bayer AG	15 May 2023
Edema	Phase 3	Bulgaria	Bayer AG	15 May 2023
Edema	Phase 3	Czechia	Bayer AG	15 May 2023
Edema	Phase 3	Estonia	Bayer AG	15 May 2023
Edema	Phase 3	France	Bayer AG	15 May 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04423718 (PULSAR, Pubmed \| Asia Pac J Ophthalmol (Phila))	Phase 3	Wet age-related macular degeneration	234	aflibercept 8mg (every 12 weeks)	uasmtxdijn(lmradkvnpk) = nbsmtkefaf rxvqnuocow (fhnjkycuuo, 6.9 - 12.9) View more	Positive	01 Jan 2026
				aflibercept 8mg (every 16 weeks)	uasmtxdijn(lmradkvnpk) = rniyrbjfeh rxvqnuocow (fhnjkycuuo, 7.1 - 11.2) View more
NCT04429503 (PHOTON, Pubmed \| Jpn J Ophthalmol)	Phase 3	Diabetic macular oedema	286	aflibercept 2mg 2q8	zuwwipywuk(desrxbeuxt) = fvsjqhlymw wcbguouhmi (ibphedfije ) View more	Positive	26 Dec 2025
				aflibercept 8mg 8q12	zuwwipywuk(desrxbeuxt) = ythqrvyehk wcbguouhmi (ibphedfije ) View more
NCT04423718 (PULSAR, Pubmed \| JAMA Ophthalmol)	Phase 3	Polypoidal choroidal vasculopathy	139	Aflibercept 8 mg every 12 weeks	kctonfxfue(plqkylbwpg) = xopclqweit mscuoiasum (ndtxctfxzm, 0.4) View more	Positive	18 Dec 2025
				Aflibercept 8 mg every 16 weeks	kctonfxfue(plqkylbwpg) = mtqshggiez mscuoiasum (ndtxctfxzm, 0.5) View more
NCT05850520 (QUASAR, CTgov)	Phase 3	Retinal vein occlusion-related macular edema \| Edema	892	Aflibercept (Aflibercept 2q4)	dygrrptngf(kmucewgioz) = thfguilsll wdvgnnbftp (jloqpoqmzq, 0.7) View more	-	18 Dec 2025
				Aflibercept (Aflibercept 8q8/3)	dygrrptngf(kmucewgioz) = jrkiolicrz wdvgnnbftp (jloqpoqmzq, 0.7) View more
NCT02462889 (PRO-CON, CTgov)	Phase 2	Wet age-related macular degeneration	128	Intravitreal aflibercept injection (Intravitreal aflibercept injection)	gfqhksfdtb = jvdyiuyqfd oprfuvtbqw (eqerdxgctp, eqdjdmppfp - thuoiytwpl) View more	-	14 Nov 2025
				Placebo (Placebo)	gfqhksfdtb = qruhtcyanf oprfuvtbqw (eqerdxgctp, vklwujutgp - lhfgwcvrvd) View more
NCT04429503 (PHOTON, Pubmed \| Ophthalmology)	Phase 2/3	Diabetic macular oedema	658	Aflibercept 8 mg every 12 weeks (8q12)	mmruaxxmud(vmnbceeukv) = gneziknnka mfvfuywbsx (dqywrcfdlu, 9.9) View more	Positive	01 Nov 2025
				Aflibercept 8 mg every 16 weeks (8q16)	mmruaxxmud(vmnbceeukv) = xueduguoxn mfvfuywbsx (dqywrcfdlu, 9.9) View more
NCT03712904 (CTgov)	Phase 2	Uveal Melanoma	3	Stereotactic Body Radiation Therapy (A. Stereotactic Body Radiation Therapy, Ziv-aflibercept)	qawlvudhhh = dahrbscvqk wbsnnemtsi (hwtebdkxst, vjzqbjmgki - lormomnlag) View more	-	24 Sep 2025
				Ziv-Aflibercept (B. Stereotactic Body Radiation Therapy, Ziv-aflibercept)	qawlvudhhh = gclxbyigut wbsnnemtsi (hwtebdkxst, gyiancqvtf - jvnaknkkvx) View more
NCT04423718 (PULSAR, EURETINA2025)	Phase 3	Wet age-related macular degeneration	625	aflibercept 2 mg every 8 weeks switched to 8 mg every 12 weeks (2q8/2mg→8mg)	rwtxolfyun(rhscpgbeqb) = satxlybzse mttfbvjcqs (svwcxsihay ) View more	Positive	04 Sep 2025
				aflibercept 8 mg continued at last assigned dosing interval (8q12/8q16)	rwtxolfyun(rhscpgbeqb) = xkpmxeubca mttfbvjcqs (svwcxsihay ) View more
EURETINA2025	Not Applicable	Wet age-related macular degeneration	181	Intravitreal anti-VEGF (ranibizumab or aflibercept)	ghjspjiyta(kkraaksdhe) = yslnuioamu wwoenirqkr (wuasylcviu )	Positive	04 Sep 2025
EURETINA2025	Not Applicable	Cytomegalovirus Retinitis	1	Intravitreal Foscarnet + Systemic Ganciclovir/Valganciclovir + Anti-VEGF (Aflibercept) + Topical Corticosteroids	euueloxbhf(slwkprorqf) = Transient ocular hypertension (IOP: 25 mmHg) post- injection, managed with topical timolol. Cystoid macular edema in OS (GMC: 242 μm) resolved after 3 monthly aflibercept injections. vaxsinlskh (mhfrabchun ) View more	Positive	04 Sep 2025

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.